WO1999001156A1 - Bouchons scleraux d'acide polylactique - Google Patents
Bouchons scleraux d'acide polylactique Download PDFInfo
- Publication number
- WO1999001156A1 WO1999001156A1 PCT/JP1998/002916 JP9802916W WO9901156A1 WO 1999001156 A1 WO1999001156 A1 WO 1999001156A1 JP 9802916 W JP9802916 W JP 9802916W WO 9901156 A1 WO9901156 A1 WO 9901156A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- molecular weight
- polylactic acid
- weight polylactic
- drug
- scleral
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
Definitions
- the present invention relates to a novel composition scleral plug for the treatment or prevention of a retinal or vitreous disorder.
- a scleral plug made of a biodegradable copolymer that can be easily inserted through a small scleral incision generated during vitreous surgery or the like has been devised (see US Patent No. 5,707,643). ).
- This scleral plug is formed from a lactic acid copolymer containing lactic acid units and glycolic acid units containing a drug, and the drug is slowly released into the vitreous body using the biodegradability of the copolymer. It is intended to treat vitreous and retinal diseases.
- the scleral plug is inserted through a small scleral incision that occurs during vitreous surgery, etc., but has enough strength that it does not break or break even when operated with forceps at the time of surgery. It must have the function of releasing the drug slowly and then have the property of being decomposed and absorbed. Therefore, in the scleral plug described in US Pat. No. 5,707,643, it is preferable that the molecular weight (weight average) be 10,000 to 100,000, and lactic acid and glycol are used. It has been proposed to take advantage of the properties of acids and use them in appropriate ratios. However, scleral plugs using a copolymer of lactic acid and glycolic acid have room for improvement in terms of sustained drug release.
- the hydrolysis rate of the plug is designed to be slow, so that the oligomers and monomers generated by the hydrolysis smoothly move out of the matrix. It does not elute into the matrix and accumulates gradually in the matrix. Therefore, the internal osmotic pressure gradually increases, and the drug may be released at once with the collapse of the plug. Therefore, it is not easy to accurately release a certain amount of a drug to the end, and its improvement has been demanded. Disclosure of the invention
- the scleral plug of the present invention is characterized in that it is formed of a mixture of high molecular weight polylactic acid and low molecular weight polylactic acid. Start to release slowly. At that time, the entire plug gradually changes to a porous structure. Next, high molecular weight polylactic acid with low hydrolyzability Gradually decomposes, but the hydrolysis-generated oligomers and monomers are smoothly eluted out of the matrix through the porous structure, so that the release of the drug until the plug disintegrates. Can be controlled at a constant speed.
- High molecular weight polylactic acid refers to polylactic acid having a molecular weight (weight average, the same applies hereinafter) of 40,000 or more
- low molecular weight polylactic acid refers to polylactic acid having a molecular weight of 40,000 or less.
- polylactic acid having a molecular weight of 40,000 is not simultaneously used as a high molecular weight polylactic acid and a low molecular weight polylactic acid.
- the drug release period that is, the decomposition rate of the plug, the molecular weight is actually set to 1,000,000 or less.
- the molecular weight of the low-molecular-weight polylactic acid is actually set to 3,000 or more in consideration of the drug release rate.
- the release of the drug can be controlled by appropriately selecting the molecular weight of the high molecular weight polylactic acid and the low molecular weight polylactic acid to be used, and the mixing ratio thereof.
- the scleral plug of the present invention is particularly preferably used when it is required to release a drug over a long period of time, but the duration of release of the drug is based on the molecular weight of the high molecular weight polylactic acid used mainly. Can be determined based on For example, based on 100,000 to 200,000 high molecular weight polylactic acid, the release period can be set to about 6 months to 1 year, and 40,000 to 100,000 high molecular weight polylactic acid can be used. Based on this, the release period can be set to several weeks to half a year. If 200,000 or more high molecular weight polylactic acid is used, the plug can have a longer-term sustained release.
- the molecular weight of the high molecular weight polylactic acid is selected taking into account the possible content and effective concentration of the drug.
- the main role of low-molecular-weight polylactic acid is to make the plug porous and to control the release of the drug constantly, but the effect mainly affects the blending ratio of low-molecular-weight polylactic acid. Is performed. If the blending ratio of the low molecular weight polylactic acid is too large, the initial release rate of the drug is increased, and it is difficult to keep the drug release constant over a long period of time. On the other hand, if the compounding ratio is too small, the porous structure cannot be improved, and the oligomers and monomers generated by the hydrolysis will not be smoothly eluted.
- the mixing ratio of high molecular weight polylactic acid and low molecular weight polylactic acid is usually 90/10 to 50 Z50, preferably 9010 to 7030, and most preferably. Is selected to be about 80 Z20.
- the release period and release amount of the drug are controlled basically by the molecular weight of the high molecular weight polylactic acid and the blending ratio of the low molecular weight polylactic acid.
- the duration of drug release is also affected by the molecular weight of the low molecular weight polylactic acid.
- Low molecular weight Decreasing the molecular weight of the polylactic acid slightly increases the drug release rate, and increasing it increases the drug release rate slightly.
- the molecular weight of the low molecular weight polylactic acid plays a role in fine-tuning the release period.
- the molecular weight of the low molecular weight polylactic acid can be appropriately varied depending on the desired release period, but is usually selected within the range of 3,000 to 40,000, and more preferably 5,000 to 20,000.
- the molecular weight is 10,000 or more, and when using a high molecular weight polylactic acid of 40,000 or more as in the present invention, sufficient strength is maintained. are doing.
- DL-form, L-form or D-form as polylactic acid
- DL-body or L-body it is preferable to use DL-body or L-body.
- the shape of the plug is similar to the shape and size disclosed in U.S. Pat. No. 5,707,643, that is, a nail having a head portion and a shaft portion. What is necessary is just to use what has the tip part of the shaft part formed in the acute angle shape.
- the scleral plug of the present invention is used for treating or preventing various diseases of the retina and the vitreous body. Specific diseases include viral and bacterial infections, proliferative vitreoretinopathy accompanied by changes in the growth of new blood vessels and retinal cells, retinal hemorrhage due to various causes, retinal detachment, retinoblastoma, etc. No.
- the drug to be contained is not limited and can be selected according to the disease.
- an antiviral agent such as gancyclovir
- doxorubicin hydrochloride or the like is used.
- the content of the drug may be appropriately increased or decreased according to the type of the drug, the required effective concentration of the drug, the release period of the drug, the symptoms, and the like.
- gancyclovir it is usually l to 4 mg, preferably 1.5 to 2.5 mg.
- the weight of the scleral plug of the present invention is about 8 to 1 O mg, but the content of the drug is determined in consideration of the balance between the sustained release effect and the amount required for treatment.
- a plurality of scleral plugs of the present invention can be used at the same time, and when the effective concentration of the drug cannot be maintained, a new scleral plug can be exchanged. No special technology is required for the production of the scleral plug of the present invention. It can be obtained by processing.
- Figure 1 shows a mixture of a high-molecular-weight polylactic acid (PLA-13000) having a molecular weight of 130,000 and a low-molecular-weight polylactic acid (PLA-500) having a molecular weight of 5,000 in a specific ratio.
- PSA-13000 high-molecular-weight polylactic acid
- PLA-500 low-molecular-weight polylactic acid
- Scleral plug formed from a mixture of high molecular weight polylactic acid (PLA-13000) and low molecular weight polylactic acid (PLA-10000) having a molecular weight of 10,000 in a specific ratio Fig.
- Fig. 3 shows a high molecular weight polylactic acid (PLA- 13,000) and a low molecular weight polylactic acid with a molecular weight of 20,000 (PLA-2000) in a specific ratio.
- Fig. 4 shows the high molecular weight polylactic acid (PLA-1) having a molecular weight of 130,000.
- Fig. 5 shows the high molecular weight polylactic acid with a molecular weight of 70,000 (PLA-700).
- GCV gancyclovir
- Fig. 8 shows the molding from a mixture of high molecular weight polylactic acid (PLA-40000) with a molecular weight of 40,000 and low molecular weight polylactic acid (PLA-500) with a molecular weight of 5,000 at a specific ratio.
- High molecular weight polylactic acid with a molecular weight of 130,000 (800 mg), low molecular weight polylactic acid with a molecular weight of 5,000 (200 mg) and gancyclovir (250 mg) are dissolved in acetic acid (10 ml). And the resulting solution The liquid was freeze-dried to obtain a fine powder. A portion of this fine powder was formed into a scleral plug on a hot plate to obtain the desired scleral plug. The content of ganciclovir per scleral plug (about 1 mg) thus obtained is about 2 mg.
- the molecular weight of the high-molecular-weight polylactic acid was 130,000, 70,000, and the molecular weight of the low-molecular-weight polylactic acid was 3000, 5,000, 10,000, 20,000, 40,000.
- High molecular weight polylactic acid Z The ratio of low molecular weight polylactic acid is 90 Z 10, 85/2 5.80 / 2 0.75 / 25, 70/30, 60/40> 50 50 scleral plugs are obtained.
- the amount of gancyclovir was about 1 mg, 2 mg, 3 mg and 4 mg per scleral plug.
- Example 1 The scleral plug produced in Example 1 was shaken in a phosphate buffer (0.1 M, pH 7.4) to elute the drug (Ganshiku Mouth Building). The eluate was collected over time and replaced with fresh buffer. This operation was repeated. The absorbance of the eluate at 254 nm was measured using a spectrophotometer to determine the amount of drug eluted. Examples of measurement results are shown in Figs. During the dissolution test, it was separately confirmed that the drug (gancyclovir) did not degrade. The results shown in FIGS. 1-8 teach the following. 1. Change in the blending ratio of high molecular weight polylactic acid (HPLA) and low molecular weight polylactic acid (LPLA)
- the longer the molecular weight of HPLA the longer the drug release period. For example, comparing FIGS. 1 and 5, when the molecular weight of HPLA is 130,000, the release period is about 300 days, and when it is 70,000, the release period is about 200 days.
- the release period of the drug becomes slightly longer as the molecular weight of LPLA increases. For example, comparing FIG. 1 and FIG. 4, when the molecular weight of LPLA is 5,000, the release period is about 300 days, and when it is 40,000, the release period is about 350 to 400 days.
- the present invention provides a novel composition scleral plug for treating or preventing a retinal or vitreous disorder.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002294714A CA2294714A1 (en) | 1997-07-02 | 1998-06-30 | Polylactic acid scleral plugs |
EP98929748A EP0992244A4 (en) | 1997-07-02 | 1998-06-30 | SCLERAL PLUGS OF POLYLACTIC ACID |
NO996569A NO996569L (no) | 1997-07-02 | 1999-12-30 | Polymelkesyreskleralplugg |
US09/475,371 US6488938B1 (en) | 1997-07-02 | 1999-12-30 | Polylactic acid scleral plug |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP17682397 | 1997-07-02 | ||
JP9/176823 | 1997-07-02 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/475,371 Continuation US6488938B1 (en) | 1997-07-02 | 1999-12-30 | Polylactic acid scleral plug |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999001156A1 true WO1999001156A1 (fr) | 1999-01-14 |
Family
ID=16020475
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1998/002916 WO1999001156A1 (fr) | 1997-07-02 | 1998-06-30 | Bouchons scleraux d'acide polylactique |
Country Status (6)
Country | Link |
---|---|
US (1) | US6488938B1 (ja) |
EP (1) | EP0992244A4 (ja) |
KR (1) | KR20010014384A (ja) |
CA (1) | CA2294714A1 (ja) |
NO (1) | NO996569L (ja) |
WO (1) | WO1999001156A1 (ja) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6726918B1 (en) | 2000-07-05 | 2004-04-27 | Oculex Pharmaceuticals, Inc. | Methods for treating inflammation-mediated conditions of the eye |
ES2250504T3 (es) | 2000-11-29 | 2006-04-16 | Allergan Inc. | Prevencion del rechazo de injerto en el ojo. |
US20050048099A1 (en) | 2003-01-09 | 2005-03-03 | Allergan, Inc. | Ocular implant made by a double extrusion process |
US20040137059A1 (en) * | 2003-01-09 | 2004-07-15 | Thierry Nivaggioli | Biodegradable ocular implant |
US20050244469A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Extended therapeutic effect ocular implant treatments |
US8425929B2 (en) | 2004-04-30 | 2013-04-23 | Allergan, Inc. | Sustained release intraocular implants and methods for preventing retinal dysfunction |
US8529927B2 (en) | 2004-04-30 | 2013-09-10 | Allergan, Inc. | Alpha-2 agonist polymeric drug delivery systems |
US20050244463A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular vasculopathies |
US8685435B2 (en) | 2004-04-30 | 2014-04-01 | Allergan, Inc. | Extended release biodegradable ocular implants |
JP5008015B2 (ja) † | 2004-12-27 | 2012-08-22 | 株式会社豊田中央研究所 | 脂肪族ポリエステル組成物及びその成形体 |
US20060233858A1 (en) * | 2005-03-08 | 2006-10-19 | Allergan, Inc. | Systems and methods providing targeted intraocular drug delivery |
CA2619552A1 (en) * | 2005-08-18 | 2007-02-22 | Smith & Nephew, Plc | Multimodal high strength devices and composites |
US20070149640A1 (en) * | 2005-12-28 | 2007-06-28 | Sasa Andjelic | Bioabsorbable polymer compositions exhibiting enhanced crystallization and hydrolysis rates |
US8236904B2 (en) | 2005-12-28 | 2012-08-07 | Ethicon, Inc. | Bioabsorbable polymer compositions exhibiting enhanced crystallization and hydrolysis rates |
US7902303B2 (en) * | 2005-12-30 | 2011-03-08 | Industrial Technology Research Institute | Aliphatic polyester polymer compositions and preparation method thereof |
US8802128B2 (en) | 2006-06-23 | 2014-08-12 | Allergan, Inc. | Steroid-containing sustained release intraocular implants and related methods |
AU2008240418B2 (en) | 2007-04-18 | 2013-08-15 | Smith & Nephew Plc | Expansion moulding of shape memory polymers |
ATE547129T1 (de) | 2007-04-19 | 2012-03-15 | Smith & Nephew Inc | Multimodale formgedächtnis-polymere |
EP2150288B1 (en) | 2007-04-19 | 2011-04-13 | Smith & Nephew, Inc. | Graft fixation |
US9095506B2 (en) | 2008-11-17 | 2015-08-04 | Allergan, Inc. | Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof |
JP2010232895A (ja) * | 2009-03-26 | 2010-10-14 | Fuji Xerox Co Ltd | 通信制御装置及び情報処理装置 |
MX361709B (es) | 2009-11-09 | 2018-12-07 | Allergan Inc | Composiciones y metodos para estimular el crecimiento del cabello. |
US20140073539A1 (en) * | 2012-09-07 | 2014-03-13 | Mitsui Chemicals, Inc. | Aqueous dispersion and additives for fracturing work |
BR112015019546A2 (pt) | 2013-02-15 | 2017-07-18 | Allergan Inc | implante de distribuição de drogas prolongado |
US20170072113A1 (en) | 2015-09-14 | 2017-03-16 | Ethicon, Inc. | Bimodal molecular weight copolymers of lactide and glycolide |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0517370A (ja) * | 1990-11-30 | 1993-01-26 | Senju Pharmaceut Co Ltd | 徐放性眼内埋込み用製剤 |
JPH06312943A (ja) * | 1993-02-26 | 1994-11-08 | Santen Pharmaceut Co Ltd | 生体分解性強膜プラグ |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5707643A (en) * | 1993-02-26 | 1998-01-13 | Santen Pharmaceutical Co., Ltd. | Biodegradable scleral plug |
CA2118515A1 (en) * | 1993-02-26 | 1994-02-23 | Yuichiro Ogura | Biodegradable scleral plug |
US5466233A (en) * | 1994-04-25 | 1995-11-14 | Escalon Ophthalmics, Inc. | Tack for intraocular drug delivery and method for inserting and removing same |
JP3309175B2 (ja) * | 1996-03-25 | 2002-07-29 | 参天製薬株式会社 | タンパク性薬物含有強膜プラグ |
-
1998
- 1998-06-30 CA CA002294714A patent/CA2294714A1/en not_active Abandoned
- 1998-06-30 WO PCT/JP1998/002916 patent/WO1999001156A1/ja not_active Application Discontinuation
- 1998-06-30 KR KR1019997012551A patent/KR20010014384A/ko not_active Application Discontinuation
- 1998-06-30 EP EP98929748A patent/EP0992244A4/en not_active Withdrawn
-
1999
- 1999-12-30 NO NO996569A patent/NO996569L/no not_active Application Discontinuation
- 1999-12-30 US US09/475,371 patent/US6488938B1/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0517370A (ja) * | 1990-11-30 | 1993-01-26 | Senju Pharmaceut Co Ltd | 徐放性眼内埋込み用製剤 |
JPH06312943A (ja) * | 1993-02-26 | 1994-11-08 | Santen Pharmaceut Co Ltd | 生体分解性強膜プラグ |
Also Published As
Publication number | Publication date |
---|---|
NO996569D0 (no) | 1999-12-30 |
EP0992244A1 (en) | 2000-04-12 |
EP0992244A4 (en) | 2001-01-17 |
CA2294714A1 (en) | 1999-01-14 |
KR20010014384A (ko) | 2001-02-26 |
US6488938B1 (en) | 2002-12-03 |
NO996569L (no) | 2000-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1999001156A1 (fr) | Bouchons scleraux d'acide polylactique | |
JP6700348B2 (ja) | 持続型薬物送達インプラント | |
US5707643A (en) | Biodegradable scleral plug | |
JP3116489B2 (ja) | 徐放性眼内埋込み用製剤 | |
JP2008540552A5 (ja) | ||
Kitazawa et al. | Trabeculectomy with mitomycin: a comparative study with fluorouracil | |
DE60116052T2 (de) | Polymermischungen als bioabbaubare matrizen zur herstellung von biokompositen | |
WO1994018921A1 (fr) | Bouchon de sclerotique biodegradable | |
JP2009529538A (ja) | サーチュイン活性化剤を用いる眼処置 | |
JP2002522469A (ja) | 限局的組織癒着バリアおよび薬物送達システムの形成方法 | |
Kim et al. | A transparent artificial dura mater made of silk fibroin as an inhibitor of inflammation in craniotomized rats | |
JP2009019038A (ja) | 非ポリマー持続性解離供給システム | |
JP2013067644A (ja) | 眼用マイクロインプラントの製造方法 | |
JP2007535552A5 (ja) | ||
CN111407774B (zh) | 一种眼科用组合物及其制备方法 | |
WO2014066658A1 (en) | Ketorolac-containing sustained release drug delivery systems | |
CN101502458A (zh) | 治疗性角膜接触镜 | |
CN108883081A (zh) | 蛋白酶体抑制剂治疗眼部疾病的用途 | |
WO1997035621A1 (fr) | Obturateur scleral contenant des medicaments proteiniques | |
AU2019290582A1 (en) | Drug delivery systems comprising a neurotrophic agent, an apoptosis signaling fragment inhibitor (FAS) or FAS ligand (FASL) inhibitor, a tumor necrosis factor-alpha (TNF-alpha) or TNF receptor inhibitor, a mitochondrial peptide, an oligonucleotide, a chemokine inhibitor, or a cysteine-aspartic protease | |
JPH1170138A (ja) | ポリ乳酸強膜プラグ | |
CN1233172A (zh) | 继发性白内障抑制剂 | |
JP3000187B2 (ja) | 生体分解性強膜プラグ | |
EP1125575B1 (en) | Perfusate preparation for ophthalmic operation | |
JPS597684B2 (ja) | コラ−ゲンを用いた眼用徐放性制御医薬剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 98806761.7 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA CN KR NO US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 09471584 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09475371 Country of ref document: US Ref document number: 1019997012551 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2294714 Country of ref document: CA Ref document number: 2294714 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998929748 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1998929748 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1019997012551 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998929748 Country of ref document: EP |
|
WWR | Wipo information: refused in national office |
Ref document number: 1019997012551 Country of ref document: KR |